logo-loader

Amryt Pharma looking to replicate success of Lojuxta drug

Published: 08:28 26 Sep 2018 EDT

Amryt Pharma

Amryt Pharma PLC's (LON:AMYT) Rory Nealon tells Proactive that the company is actively seeking to expand its commercial portfolio following the success of its Lojuxta treatment.

The pharmaceutical firm reported a narrowed loss before tax of €11.3mln for the first half of the year, less than a €13.8mln loss previously, while revenues grew to €7mln from €6.1mln.

Revenues were boosted by a 14.6% increase in sales of the Lojuxta drug to €6.6mln.

Caledonia Mining tackles 2023 challenges with optimism for 2024 as it...

Caledonia Mining Corporation PLC (AIM:CMCL, NYSE-A:CMCL) chief executive Mark Learmonth tells Proactive's Stephen Gunnion the company faced a challenging 2023, primarily due to poor production in the first half of the year at its core asset, the Blanket Mine in Zimbabwe, and an underperformance...

19 minutes ago